Description
A prodrug form of paclitaxel; comprised of paclitaxel conjugated to 1,18-octadecanedioic acid; does not promote tubulin polymerization in vitro at 10 μM; cytotoxic to HT-1080, PANC-1, and HT-29 cells (IC50 = 12, 2.48, and 8.62 nM, respectively) as a 5:1 mixture with HSA; mixture with HSA reduces tumor growth and increases survival in an HT-1080 mouse xenograft model in a dose-dependent manner
Formal name: octadecanedioic acid-1-[(1R,2S)-2-(benzoylamino)-1-[[[(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl]oxy]carbonyl]-2-phenylethyl] ester
Synonyms: 1,18-Octadecanedioic Acid-Paclitaxel|ODDA-PTX|PTX-FA18
Molecular weight: 1,150.40
CAS: 2089211-45-8
Purity: ≥98%
Formulation: A crystalline solid